Colorectal Cancer Test Drives Q4 Revenue Increase for GeneNews | GenomeWeb

NEW YORK (GenomeWeb News) — Molecular diagnostics company GeneNews saw its fourth-quarter revenues rise sharply year over year after its colorectal cancer test was approved for marketing in New York, the company reported after the close of the market on Tuesday.

For the three months ended Dec. 31, 2012, the Toronto-based firm posted revenues of C$59,630 (US$58,658), up from C$2,840 a year ago. Revenues were derived completely from its ColonSentry gene expression assay for assessing a patient's risk for colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.